CommanderAI | $5,000,000 | (Nov 6, 2025)
Procurement Sciences | $30,000,000 | (Nov 6, 2025)
Certified by Founder
Lodge
Braveheart Bio
start up
United States
- San Francisco, California
- 06/11/2025
- Series A
- $185,000,000
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
- Industry Biotechnology Research
- Website https://www.braveheart.bio/
- LinkedIn https://www.linkedin.com/company/braveheart-bio/
Freeda | $3,912,210 | (Nov 6, 2025)
NEOK Bio | $75,000,000 | (Nov 6, 2025)
LambdaVision, Inc. | $7,000,000 | (Nov 6, 2025)
Flux XII Inc. | $3,950,000 | (Nov 6, 2025)
Boostie | $500,000 | (Nov 6, 2025)
Rilevera | $3,000,000 | (Nov 6, 2025)
Wisconsin Alumni Research Foundation (WARF) | $3,950,000 | (Nov 6, 2025)
Cactus | $7,000,000 | (Nov 6, 2025)
GitLaw | $30,000,000 | (Nov 6, 2025)